Skip to content
2000
Volume 10, Issue 9
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Imaging the N-methyl-D-aspartate receptors (NMDARs) in the living human brain by positron emission tomography (PET) or single photon emission computed tomography (SPECT) would provide useful information on the role of these receptors in ischemia and in various neurological disorders such as degenerative diseases, epilepsy or schizophrenia. To assess NMDAR radiotracer development and to propose perspectives, we overviewed the PET and SPECT candidate radioligands developed until now. Labelled molecules of interest were classified in three groups according to their binding site: intrachannel pore site blockers, glycine site inhibitors and NR2B selective subunit antagonists.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955710791608299
2010-08-01
2025-10-13
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955710791608299
Loading

  • Article Type:
    Research Article
Keyword(s): Imaging; NMDA receptors; PET; radiopharmaceutical; radiotracer; SPECT
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test